News
News
We are glad to share with you about the results of our work, company news, and give you timely developments and personnel appointment and removal conditions.
07 2026-01 Subjects was Grouped for Clinical Test on the Quadrivalent Meningococcal Conjugate Vaccine (MCV4) — Another Key Product of AIM Vaccine
Another key product — quadrivalent meningococcal conjugate vaccine (MCV4) has been developed independently by AIM Vaccine. On March 15, the clinical test was officially carried out at Yanshan Disease Prevention and Control Center in Yunnan Province and related subjects were grouped.
07 2026-01 Phase II Clinical Data on AIM’s mRNA Impressive and Significantly Effective On Omicron
The data from the phase II clinical trial of mRNA (LVRNA009) targeting Covid-19 - independently developed by AIM Vaccine, have been known to the public. The live virus-neutralizing antibodies tested by Wuhan Institute of Virology, CAS, revealed that, the geometric mean titer (GMT) of the live virus-neutralizing antibodies 14 days after full-course vaccination of mRNA, was 994.9 in the adult medium-dose group and 1405.7 in the adult high-dose group. These figures prove mRNA is fairly strong in immunogenicity. mRNA (LVRNA009), one of the earliest vaccines against Covid-19 with clinical trial permission, has got the top spot in advancing its clinical progress. It is significantly better than its counterparts in clinical effects.
07 2026-01 AIM Vaccine Publishes the Latest Preclinical Data of mRNA Rabies Vaccine in "npj Vaccines": Only Two Doses are Needed to Provide 100% Safe and Effective Immune Protection
Vice President and Chief Research Officer Zhang Fan, and General Manager of AIM Lifanda Peng Yucai, recently published the preclinical research data of the mRNA rabies vaccine LVRNA001 in the international authoritative academic journal "npj Vaccines": Only two vaccinations are needed to provide 100% safe and effective immune protection. This has laid a solid foundation for the next stage of research on human rabies mRNA vaccines.
07 2026-01 Humoral and Cellular Immunity of The Mrna Rsv Vaccine Were Significantly Higher Than Those of Internationally Marketed Products Application for Clinical Trial in The U.S.
Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The application for clinical trial of mRNA RSV (respiratory syncytial virus) vaccines has been submitted to the U.S. Food and Drug Administration (“FDA”) recently.
10 2026-03 What Is Rabies Vaccine Vero Cell and Why Is It Essential for Modern Rabies Prevention?
Rabies remains one of the deadliest viral infections known to humanity, with an almost 100% fatality rate once symptoms appear. Fortunately, modern biotechnology has provided highly effective vaccines that prevent this tragic outcome. Among these, Rabies Vaccine Vero Cell has become one of the most widely trusted and advanced solutions used in both post-exposure and pre-exposure immunization programs worldwide.